GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

by barry-jtcir | May 21, 2024 | Press Releases

Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion1 Company targeting IND filing for GRI-0803...

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

by barry-jtcir | May 20, 2024 | Press Releases

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung inflammation Company advancing Phase 2a biomarker...

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

by barry-jtcir | May 14, 2024 | Press Releases

Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

by barry-jtcir | May 13, 2024 | Press Releases

Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoing progress of Investigational New Drug (IND) enabling studies in...

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

by barry-jtcir | Apr 29, 2024 | Press Releases

LA JOLLA, CA, April 29, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

by barry-jtcir | Apr 25, 2024 | Press Releases

Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators...